Know How Inpefa Stacks Up to Other SGLT2 Inhibitors
New Inpefa (sotagliflozin) will try to compete with other SGLT2 inhibitors (Farxiga, Jardiance, etc).
Inpefa is NOT approved for managing type 2 diabetes yet...although A1c lowering seems similar to other SGLT2 inhibitors.
Instead, expect reps to tout Inpefa to reduce heart failure risk...especially for patients with a recent HF hospitalization.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote